HYPE3 - -
IBOV - -

Hypera

ESG & Integrity

ESG & Integrity

At Hypera Pharma, we consider it essential that our conduct in carrying out our business is marked by integrity, compliance and transparency.

We do not tolerate or encourage unethical practices or violations of the current legislation or our Code of Ethical Conduct, of our policies and internal rules, including corruption, fraud, and other irregularities provided in the Law 12.846/13, among others.

Click here to learn more about our Ethical & Compliance Program, our Code of Ethical Conduct and our Anti-Corruption Policy. If you have any questions, please contact compliance@hypera.com.br.

Annual Reports

Sustainability Strategy

In 2025, the materiality assessment conducted in 2024 was discussed and approved by the Governance and Sustainability Committee and by the Board of Directors, with the objective of identifying the guiding topics for Grupo Hypera Pharma’s initiatives and supporting its long-term strategy. In line with this assessment, the Governance and Sustainability Committee and the Board of Directors also approved the Group’s new sustainable commitments and initiatives for the 2026 to 2030 period.

Integrated perspective

Access to healthcare
  • Affordability;
  • Access to healthcare.
Attraction, retention, and talent development
  • Attraction and retention of talent;
  • Training and development;
  • Occupational health and safety;
  • Diversity, equity, and anti-discrimination in operations.
Business ethics
  • Code of conduct and stakeholder engagement;
  • Responsible marketing;
  • Ethics and anti-corruption.
Product safety and quality
  • Product safety and quality;
  • Supplier management.
Commitment to innovation
  • Commitment to innovation
Waste management
  • Waste management.
Climate change
  • Climate change mitigation;
  • Energy use management.
Natural resources management
  • Water and effluent management;
  • Raw material management.

MAIN ESG HIGHLIGHTS

 

  • Hypera Pharma complies with the Novo Mercado regulation, a highly differentiated corporate governance standard in Brazil;
  • Hypera Pharma has a Statutory Audit Committee that follows the criteria of the Brazilian Securities and Exchange Commission (CVM);
  • Hypera Pharma has a Legal and Compliance Executive Board reporting directly to the CEO and the Statutory Audit Committee;
  • Hypera Pharma maintains a unified mandate for Board members of up to two years, with the possibility of re-election;
  • In 2025, 30% of the Board of Directors is independent, according to Novo Mercado criteria;
  • In 2025, 30% of the Board of Directors is composed of women;
  • In 2025, 30% of the Board of Directors is composed of foreign members;
  • 100% attendance of the Board of Directors in meetings in 2025;
  • Hypera Pharma is a signatory of the UN Global Compact and annually reaffirms its commitment and reports progress on human rights, labor, environment, and anti-corruption initiatives;
  • Since 2018, it has published its emissions in the Public Emissions Registry;
  • Since 2020, it has published its annual reports guided by the Global Reporting Initiative (GRI);
  • Since 2020, it has conducted a materiality assessment to guide its ESG strategy and reviews it periodically;
  • Since 2021, it has published its annual reports based on the global Sustainability Accounting Standards Board (SASB) framework;
  • The Company has a Governance and Sustainability Committee, which advises the Board of Directors on actions and guidelines that integrate environmental, social and governance dimensions into Hypera Pharma’s strategy;
  • Hypera Pharma is part of the FTSE4Good Index Series of the London Stock Exchange;
  • Hypera Pharma is part of B3’s Diversity Index (IDIVERSA);
  • Hypera Pharma is part of B3’s Carbon Efficient Index (ICO2);
  • Hypera Pharma follows the recommendations of the TCFD (Task Force on Climate-related Financial Disclosures) and reports its emissions to the CDP (formerly Carbon Disclosure Project).
Last updated on June 17, 2026.
Close